All three types of autosomal recessive spinal muscular atrophy map to chromosome 5q11.2-q13.3 and are associated with deletions or mutations of the SMN (survival motor neurone) gene. The availability of a test to distinguish between the SMN gene and its nearly identical centromeric copy cBCD541 allows molecular diagnosis. We have analysed patients from 24 Belgian and 34 Turkish families for the presence or absence of a deletion in the SMN gene. A homozygous deletion in the SMN gene was seen in 90% of unrelated SMA patients. A non-radioactive SSCP assay allows for a semiquantitative analysis ofthe copy number ofthe centromeric and SMN genes. Hence, direct carrier detection has become feasible under certain conditions. We observed a phenotypically normal male, father of an SMA type I patient, presenting with only a single copy of the SMN gene and lacking both copies of the cBCD541 gene. This illustrates that a reduction of the total number of SMN and cBCD541 genes to a single SMN copy is compatible with normal life. In another SMA type I family, there is evidence for a de novo deletion of the centromeric gene in a normal sib. This observation illustrates the susceptibility of the SMA locus to de novo deletions and rearrangements.
Spinal muscular atrophy (SMA) is a lethal autosomal recessive disease common in white populations (1 in 6000 newborns).' SMA is characterised by degeneration of the anterior horn cells of the spinal cord, leading to symmetrical paralysis of voluntary muscles with muscular atrophy. Three different clinical syndromes can be defined on the basis of severity. The acute form of SMA, SMA type I (WerdnigHoffmann disease) starts with hypotonia and weakness in utero or within the first few months of life. These children are never able to sit unsupported. The majority of these children die within the first three years of life because of recurrent respiratory infections. In the intermediate type of SMA (Dubowitz disease or SMA type II) onset is usually between 3 and 15 months of age. These children learn to sit without support but never manage to stand or walk unaided. They survive beyond 4 years of age until adolescence or later. The onset of the chronic form of SMA, SMA type III (Kugelberg-Welander disease) is after the age of 2 years and is characterised by proximal muscle weakness, predominantly of the legs. These patients manage to stand and walk unsupported, but have problems with running, jumping, and climbing. Their 3 However, further analysis showed that other loci are probably involved in the pathogenesis. In summary, it is hypothesised that mutations in the SMN gene are the major determinant of the SMA phenotype, whereas the extent of the deletions, which may include the NAIP gene, may correlate with the severity of the disease. 2 3 We report on the presence or absence of a deletion in the SMN gene in 58 SMA patients, using a non-radioactive SSCP (single stranded conformation polymorphism) assay. This test discriminates between the centromeric gene CBCD541 and telomeric SMN gene and allows for the quantification of the different copies. In some cases it can be used for carrier testing. Together with the overall data, two unusual cases are described.
Materials and methods

SUBJECTS AND FAMILY DATA
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in 13 cases in which homozygous deletions of exon 8 of the SMN gene had been found in the affected sib (13 pairs of parents tested). In type I was confirmed in three ,patients of four patients in four different families, the sh origin. Two of these patients are the SSCP results indicated equal doses of exon 8 of ict of first cousin marriages. However, the centromeric and telomeric genes (subjects ;is of the CVS and MAP-1B markers did typed as 1Cen/lTel or 2Cen/2Tel). However, iow homozygosity, which might suggest by determining the deletion status of sibs in )es not prove that the disease is not linked these families and by following the segregation omosome 5q in these patients. Diagnostic of the dinucleotide repeat alleles, these subjects es in a Turkish type II patient include a were typed as lCen/lTel (the families were ig nerve conduction velocity on EMG, analysed as those shown in fig 4) . Thus, no may take it beyond classical SMA. These evidence for de novo deletions in any of these will be further investigated at the mo-patients was withheld. The SSCP method has r level by sequence analysis. fig lA) . Exon 5 of the NAIP confirmed that the signal was the result of -ould also be amplified in the proband of contamination with maternal DNA and that the 21 (fig 1B) . The results are shown in pattern should not be interpreted as that of an unaffected carrier (data not shown). Two familial cases are described in further detail because of interesting observations. These cases will be further investigated by sequencing the SMN gene. On the other hand, a direct test is now available for the confirmation of clinical diagnosis without the need for a muscle biopsy and its use can be extended to atypical cases. Deletions in the SMN gene have already been identified in patients with infantile SMA and congenital heart defects9 and in a patient with the fetal hypokinesia sequence and signs of SMA.10 The use of the SSCP method in prenatal diagnosis has been previously reported. 8 We have also successfully used the described non-radioactive SSCP method for prenatal diagnosis of SMN deletions, and the test allows diagnosis in cases in which no DNA of an affected sib is available. For families in which no evidence of a deletion was obtained, prenatal testing will have to be based on linked polymorphic markers alone, as before, and one should be aware of the fact that the disease may not necessarily be linked to chromosome 5q in such families.
A PCR method with restriction digestion, based on the polymorphic differences between the CBCD541 and SMN genes, has been described by van der Steege et al. " In our hands, the SSCP based test has proved reliable. It has the advantages of a non-radioactive method and it also allowed for a limited quantification of the different fragments and for carrier testing in some cases. However, the carrier status of the parents or sibs could o'nly be reliably determined whenever a dose difference was observed between the fragments of the SMN gene and of the centromeric gene. In practice, the difference between two centromeric exon fragments plus two SMN exon fragments (2Cen/ 2Tel) and one copy of each exon (1 Cen/lTel), the latter representing an SMA carrier, could not reliably be made. Given the number of people that lack both copies of the centromeric gene (4 4%, data from Lefebvre et al'), the frequency of carriers of a deletion of the cBCD541 gene must be high: 0 33 (based on Hardy-Weinberg equilibrium). This would simply mean that 33% of the SMA carriers also lack a copy of the centromeric gene, being lCen/lTel. Thus, every third "normal" SSCP result would be misinterpreted. The difference between 1Cen/OTel and 2Cen/OTel can also not be shown. This, however, would not affect the molecular diagnosis. The opposite result, OCen/lTel versus OCen/2Tel, again results in an uncertain carrier determination. These limitations diminish the value of this assay for carrier detection in general and screening for SMA is not yet possible.
It is recommended to check for both exon 7 and exon 8. The exon 8 assay detected only 94% of the deletion chromosomes identified by the exon 7 assay. The existence of this rare deletion, including exon 7 but not exon 8, has also been previously reported. '7 In practical terms, the combination of both assays offers more reliable genotyping. It would also detect patients in which a gene conversion may be present (see Lefebvre et a!2) . Similarly, the availability of the closely linked genetic markers cVS19 and MAP-lB gives confirmatory information for determination of the phase and interpretation of the SSCP data in equivocal cases, and, whenever possible, a combination ofboth techniques is recommended for prenatal diagnosis.
There is no evidence for a de novo deletion of the SMN gene in 13 cases in which the parents have been genotyped. However, we describe a de novo deletion event in the centromeric gene in a sib of an SMA type I patient. It could be suggested that the absence of a copy of the telomeric (SMN) gene in the father has facilitated the loss of the centromeric gene on the homologous chromosome during meiosis. If so, the opposite event might occur as well: the absence of the centromeric gene might facilitate the loss of the telomeric gene on the homologous chromosome, generating a disease chromosome. This would imply an increased risk for de novo deletions in carriers of a centromeric deletion. While the CBCD54 1 deletion carrier frequency is very high,' this could explain the high frequency of SMA carriers in the population. It would be interesting to use the semiquantitative SSCP assay in families with de novo SMA cases to substantiate this hypothesis. Alternatively, the accumulation of centromeric deletions may represent the silent counterpart of random telomeric or centromeric deletions, in which case the telomeric deletion frequency in the population has been reduced because of the lethal phenotype. All together, this observation stresses the instability of this chromosomal region. Other data obtained by Lefebvre et al' and by our groupl' also suggest that complex rearrangements can occur on this chromosome.
Nothing is settled yet as to the size of the deletion in SMA cases. Four patients, of types I, II, and III, have been found to carry a combination of a deletion including exon 7 only on one allele, and a larger deletion, including both exon 7 In conclusion, direct (prenatal) molecular diagnosis of SMA has become feasible by looking at the presence or absence of a single gene on chromosome 5q. However, it has become evident that this region of chromosome 5q shows some special characteristics which should lead to caution in DNA diagnosis and prenatal diagnosis.
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